secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016905
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences Q2 2022 net loss $13.5M; cash $122.1M; NMIBC trial on track
----------------------------------------------------------------------------

- Net loss $13.5M for Q2 2022 vs $8.9M in Q2 2021; R&D expense rose to $9.5M from $6.6M.
- Cash and equivalents $122.1M; sufficient to fund operations into 2024.
- On track to dose first patient in Phase 1 NMIBC trial in Q3 2022; FDA Fast Track granted.
- On track to initiate pivotal trial in early-stage choroidal melanoma in Q4 2022.
- Plans to file IND for choroidal metastases in Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017022016905/0000950170-22-016905-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017022016905/aura-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016905

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer